420,000 Shares in Humana Inc. (NYSE:HUM) Bought by Baupost Group LLC MA

Baupost Group LLC MA purchased a new stake in shares of Humana Inc. (NYSE:HUM) in the second quarter, according to its most recent filing with the SEC. The firm purchased 420,000 shares of the insurance provider’s stock, valued at approximately $156,933,000. Humana accounts for about 4.3% of Baupost Group LLC MA’s portfolio, making the stock its 8th largest position. Baupost Group LLC MA owned about 0.35% of Humana at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. lifted its position in Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after buying an additional 39 shares during the period. Hantz Financial Services Inc. purchased a new stake in shares of Humana in the second quarter worth about $35,000. Family Firm Inc. purchased a new position in Humana in the 2nd quarter worth approximately $37,000. Hollencrest Capital Management acquired a new stake in Humana during the 2nd quarter valued at $40,000. Finally, Riverview Trust Co purchased a new stake in Humana during the 2nd quarter worth $44,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Royal Bank of Canada upped their price objective on shares of Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, September 5th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $395.00 price target on shares of Humana in a research note on Friday. TD Cowen raised their price objective on Humana from $396.00 to $407.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Oppenheimer lifted their price target on shares of Humana from $370.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, August 1st. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Humana from $341.00 to $349.00 and gave the company a “hold” rating in a research note on Friday, August 2nd. Thirteen investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $398.70.

Humana Price Performance

Shares of HUM opened at $310.41 on Friday. Humana Inc. has a 12 month low of $298.61 and a 12 month high of $530.54. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66. The stock has a fifty day moving average price of $357.71 and a 200 day moving average price of $345.63. The company has a market cap of $37.40 billion, a P/E ratio of 19.33, a PEG ratio of 2.56 and a beta of 0.50.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping the consensus estimate of $5.89 by $1.07. The business had revenue of $29.54 billion during the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The company’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $8.94 earnings per share. On average, research analysts forecast that Humana Inc. will post 16 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.14%. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.